ReviewInternational journal of hepatology2018
Newer Oral Anticoagulants in the Treatment of Acute Portal Vein Thrombosis in Patients with and without Cirrhosis.
Review in International journal of hepatology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed.
- How to determine the optimal duration of anticoagulation for VTE: an evidence-based decision-analytical approach.Blood advances · 2026Article
- Population pharmacokinetics of rivaroxaban after transjugular intrahepatic portosystemic shunt.European journal of clinical pharmacology · 2026Article
- Current clinical research status and future treatment directions for liver cirrhosis combined with portal vein thrombosis.World journal of hepatology · 2025Review
- Comparing clinical outcomes of vitamin K antagonists vs non-vitamin K antagonists in anticoagulant therapy for mesenteric venous thrombosis.Journal of vascular surgery. Venous and lymphatic disorders · 2024Article
- Classification and Management of Portal Vein Thrombosis in Cirrhotic Patients: A Narrative Review.Cureus · 2024Review
- Intestinal obstruction induced by portal vein thrombosis in a female undergoing oral contraceptive therapy: a case report with comprehensive review.Annals of medicine and surgery (2012) · 2024Article
- Intestinal Obstruction as Initial Presentation of Idiopathic Portal and Mesenteric Venous Thrombosis: Diagnosis, Management, and Literature Review.Diagnostics (Basel, Switzerland) · 2024Review
- Article
- Direct oral anticoagulants in the treatment of portal vein thrombosis in patients with portal hypertension.Clinical liver disease · 2023Article
- Inferior mesenteric vein thrombosis in the setting of testosterone therapy.BMJ case reports · 2022Article
- Interventional Management of Portal Hypertension in Cancer Patients.Current oncology reports · 2022Review
- Portal vein thrombosis in a noncirrhotic patient after hemihepatectomy: A case report and review of literature.World journal of clinical cases · 2022Article
- Cost-Effectiveness of Aspirin for Extended Venous Thromboembolism Prophylaxis After Major Surgery for Inflammatory Bowel Disease.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2022Article
- 2020 Clinical Update in Liver Transplantation.Journal of cardiothoracic and vascular anesthesia · 2022Review
- Non-cirrhotic portal vein thrombosis - therapeutic challenge.Jornal vascular brasileiro · 2022Article
- High incidence of major bleeding with off-label use of edoxaban.Journal of clinical biochemistry and nutrition · 2021Article
- A network meta-analysis of direct oral anticoagulants for portal vein thrombosis in cirrhosis.Hepatology international · 2021Article
- Evidence-based clinical practice guidelines for Liver Cirrhosis 2020.Journal of gastroenterology · 2021Review
- The Natural History, Treatments, and Outcomes of Portal Vein Thrombosis in Patients With Inflammatory Bowel Disease.Inflammatory bowel diseases · 2021Article
- Aortic valve endocarditis byIDCases · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNewer oral anticoagulants (NOACs) are being utilized increasingly for the treatment of venous thromboembolism (VTE). NOAC use is the standard of care for stroke prophylaxis in nonvalvular atrial fibrillation and treatment of acute VTE involving extremities and pulmonary embolism. In contrast, most guidelines in the literature support the treatment of acute portal vein thrombosis (PVT) with low molecular weight heparin (LMWH) and vitamin K antagonists (VKA). Literature evaluating NOAC use in the treatment of acute portal vein thrombosis is sparse. This review focuses on the safety and efficacy of the use of NOACs in the treatment of acute PVT in patients, with or without concomitant cirrhosis, based on the most recent data available in the current literature.
methodsA systematic review was conducted through a series of advanced searches in the following medical databases: PubMed, BioMed Central, Cochrane, and Google Scholar. Keywords utilized were as follows: NOAC, DOAC (direct oral anticoagulants), portal vein thrombosis, rivaroxaban, apixaban, dabigatran, and edoxaban. Articles related to newer anticoagulant use in patients with portal vein thrombosis were included.
resultsThe adverse events, including bleeding events (major and minor) and the failure of anticoagulation (propagation of thrombus or recurrence of PVT), are similar between the NOACs and traditional anticoagulants for the treatment of acute PVT, irrespective of the presence of cirrhosis.
conclusionsNewer oral anticoagulants are safe and efficacious alternatives to traditional anticoagulation with low molecular weight heparin and vitamin K antagonists in the treatment of acute portal vein thrombosis with or without cirrhosis.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.